XML 81 R72.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Shareholders' Equity - Summary of Number of Shares Used to Compute Diluted Earnings Per Share (Details) - shares
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Share Capital, Reserves And Other Equity Interest [Abstract]    
Average number of shares outstanding [1] 1,225,500,000 1,249,400,000 [2]
Adjustment for stock options with dilutive effect 100,000 100,000
Adjustment for restricted shares 5,100,000 4,300,000
Average number of shares used to compute diluted earnings per share [1] 1,230,700,000 1,253,800,000 [2]
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.